What Are the Side Effects of Mounjaro and How to Manage Them?
Mounjaro (tirzepatide) is a once-weekly injectable dual GIP/GLP-1 agonist used for type 2 diabetes and weight management. Its most common side effects are gastrointestinal — nausea, diarrhoea, vomiting, constipation, indigestion and abdominal pain — and they usually cluster around dose increases before easing over time. Hydration, smaller low-fat meals and slower titration help most people; severe pain or allergy symptoms need urgent care. [2]
Check your eligibility →
How Does Mounjaro Work for Weight Loss?
Mounjaro's active ingredient, tirzepatide, is a dual agonist — it activates two incretin receptors at once, GIP and GLP-1. By influencing these pathways it reduces appetite, slows gastric emptying and improves glucose regulation, which together support weight loss alongside lifestyle changes. That same slowing of digestion is what drives most of the gastrointestinal side effects.
In India, Eli Lilly has launched Mounjaro for obesity and type 2 diabetes following regulatory clearance. Although it is primarily used to improve blood sugar control in adults with type 2 diabetes, tirzepatide has also shown meaningful weight-loss outcomes in clinical trials. [1]
In the SURMOUNT-1 trial (72 weeks, 2,539 participants with obesity/overweight without diabetes), average weight loss was about 20.9% with tirzepatide 15 mg versus about 3.1% with placebo. In that trial 90.9% of participants on 15 mg lost at least 5% of body weight, and 56.7% lost at least 20%. A 2023 systematic review of 10 trials (9,873 participants) found similar weight reduction, with gastrointestinal effects the most common tolerability issue. [3, 4]
What Are the Common Side Effects of Mounjaro?
According to the prescribing information, the most common adverse reactions with Mounjaro (reported in 5% or more of patients) are gastrointestinal: nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia (indigestion) and abdominal pain. Most are mild to moderate and tend to appear or worsen when the dose is increased, then settle as the body adjusts.
| Side effect | Why it happens | When it's most noticeable |
|---|---|---|
| Nausea | Slowed gastric emptying and incretin signalling | Starting treatment or a dose increase |
| Diarrhoea | Changes in digestion and gut signalling while adjusting | Early treatment |
| Decreased appetite | A core effect — part of how it works | Throughout; can make protein/fluid intake harder |
| Vomiting | Often alongside nausea | Early on and around dose escalation |
| Constipation | Lower food volume, slower gut movement, low fluids | Any stage |
| Indigestion | Reflux worsened by high-fat meals, alcohol, large portions | Adjustment phase |
| Abdominal pain | Usually mild, but can signal pancreatitis or gallbladder disease | Any stage — persistent pain needs review |
Before starting Mounjaro, discuss your health history and current medications with a trusted clinician so you can begin with a plan that prioritises safety and tolerability.
Why Do Side Effects Cluster During Dose Increases?
Mounjaro is started low and stepped up gradually so the gut can adapt. Each dose increase temporarily intensifies gastrointestinal effects, which then settle before the next step. The prescribing information notes that many reports of nausea, vomiting and diarrhoea occurred during dose escalation and decreased over time — so a flare after a dose change is expected, not a sign the medicine isn't working.
Illustrative representation of the escalation-linked pattern described in the label — later spikes are typically smaller and symptoms settle on a stable dose. Source: Mounjaro Prescribing Information. [2]
"Many gastrointestinal side effects occur during dose escalation and often decrease over time."
Paraphrased from the Mounjaro Prescribing Information. [2]
How Do You Manage Mounjaro Side Effects?
Most mild side effects are manageable with a few practical changes: for nausea, eat smaller plain meals and sip fluids; for diarrhoea, prioritise hydration; for constipation, add water, fibre and light movement; for indigestion, cut back on heavy high-fat meals. If symptoms are intense, not improving, or affecting hydration and nutrition, talk to your prescriber — sometimes holding a dose longer instead of escalating is the simplest fix.
A useful thing to remember: because so many GI effects concentrate around dose increases, holding a dose longer instead of escalating is often the simplest fix. That decision belongs with your prescriber — reach out sooner rather than later if symptoms affect hydration or nutrition. [2]
What Serious Risks Should You Watch For?
Rare but serious risks include pancreatitis, gallbladder disease and hypersensitivity reactions. Severe abdominal pain, facial or throat swelling, or breathing difficulty should be treated as urgent. Mounjaro also carries a boxed warning about thyroid C-cell tumours and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.
Severe or persistent abdominal pain (possible pancreatitis or gallbladder disease), facial or throat swelling, or breathing difficulty (possible hypersensitivity reaction). Do not wait for these to pass on their own.
| Safety topic | What the label says |
|---|---|
| Missed dose | Take it as soon as possible within 4 days (96 hours); otherwise skip it and take the next dose on the regular day. |
| Low blood sugar | Hypoglycaemia risk increases when combined with insulin or sulfonylureas — your clinician may adjust those medicines. |
| Pancreatitis & gallbladder | Severe abdominal pain should not be brushed aside; the label carries specific warnings. |
| Hypersensitivity | Facial/throat swelling or breathing difficulty is a medical emergency. |
| Thyroid (boxed warning) | Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2 (C-cell tumours seen in rats). |
Mounjaro delays gastric emptying and may reduce the efficacy of oral hormonal contraceptives. The label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation. Australia's TGA has published updated contraception advice consistent with this. [2, 6]
Starting Mounjaro, or struggling with side effects?
Every Karespot patient is assessed and supervised by a registered MBBS + MD (Internal Medicine) prescriber, with a dietician, clinical psychologist and health coach alongside. Dosing, side effects and progress reviews are managed at every stage — including structured, clinician-led switches between medicines.
Check Your Eligibility → Explore more guides on Kare Hub →Frequently Asked Questions
What are the most common side effects of Mounjaro?
How long do Mounjaro side effects last?
How can I reduce nausea on Mounjaro?
What are the serious side effects of Mounjaro that need urgent care?
Does Mounjaro interfere with contraceptives?
What should I do if I miss a dose of Mounjaro?
Can Mounjaro cause low blood sugar?
Is it possible to switch from Mounjaro to Wegovy?
Express Healthcare. Eli Lilly launches Mounjaro in India for obesity and type 2 diabetes. 19 Mar 2025.
expresshealthcare.in — Mounjaro India launchEli Lilly. MOUNJARO (tirzepatide) injection — Prescribing Information. US Food and Drug Administration. 2022 and later updates.
accessdata.fda.gov — Mounjaro Prescribing InformationAmerican College of Cardiology. SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity. 2022.
acc.org — SURMOUNT-1Weight loss efficiency and safety of tirzepatide: A systematic review. PLOS ONE. 2023;18(5):e0285197.
doi.org/10.1371/journal.pone.0285197Novo Nordisk. Semaglutide 7.2 mg achieved 20.7% weight loss in the STEP UP obesity trial. 17 Jan 2025.
globenewswire.com — STEP UP announcementTherapeutic Goods Administration (Australia). Updated contraception advice for Mounjaro (tirzepatide). 30 Nov 2025.
tga.gov.au — Mounjaro contraception adviceKarespot. GLP-1 Support Programme — Holistic Weight Management.
karespot.in/products/glp-1-support-programKarespot. Mounjaro Doses: What to Expect at Each Stage of Treatment. Kare Hub Blog.
karespot.in — Mounjaro Dose GuideKarespot. How to store Wegovy, Mounjaro and Ozempic and other GLP-1 medications the right way. Kare Hub Blog.
karespot.in — GLP-1 Storage GuideDr. Prakrati Garg is a Research Associate and published researcher in Biotechnology at Shoolini University, and Content Strategist at Karespot. With expertise in herbal drug development, nanotechnology, and drug delivery systems, she brings a rigorous scientific approach to Karespot's health and wellness content.
Dr. Sana Umar is an Assistant Professor at Doon Medical College and Medical Reviewer at Karespot. A Clinical Pathologist with FRCP credentials and NMC registration (UKMC Reg. 8506), she ensures all clinical content aligns with current prescribing guidelines and evidence-based best practices in GLP-1 therapy and weight management medicine.
Weight loss and lifestyle change can feel like a lonely road. At Karespot, we believe you should never have to walk it alone.
Karespot is a telehealth platform that connects patients across India with a team of MBBS + MD (Internal Medicine) specialists and Endocrinologists who provide personalised, medically supervised care. We believe that medication is a tool, not the answer alone. Real, lasting change comes from building the habits and lifestyle that carry you forward long after treatment ends.
Every Karespot patient is supported by a holistic team: a doctor who understands your metabolic health, a registered dietician who adapts your nutrition to your real life, a clinical psychologist who helps you understand your relationship with food, and a lifestyle health coach who helps you build the daily habits that last.
Delhi & NCR: New Delhi, Noida, Gurugram, Faridabad, Ghaziabad
Uttarakhand: Dehradun, Haridwar, Roorkee, Haldwani, Rudrapur, Rishikesh, Nainital, Kotdwar
Uttar Pradesh: Lucknow, Kanpur, Agra, Varanasi, Prayagraj, Meerut, Gorakhpur, Aligarh, Bareilly
Maharashtra: Mumbai, Pune, Nagpur, Nashik, Thane, Navi Mumbai, Aurangabad
Karnataka: Bengaluru, Mysuru, Mangaluru, Hubballi-Dharwad, Belagavi
Telangana: Hyderabad, Warangal, Nizamabad, Karimnagar
Punjab & Chandigarh: Amritsar, Ludhiana, Jalandhar, Patiala, Chandigarh, Mohali
Other Cities: Chennai, Kolkata, Ahmedabad, Jaipur, Surat, Kochi, Indore, Coimbatore, Bhopal, Visakhapatnam, Thiruvananthapuram
Medical Disclaimer: This article is for general informational purposes only and does not constitute medical advice. Mounjaro (tirzepatide) is a prescription medicine that must be prescribed and supervised by a qualified Internal Medicine specialist or Endocrinologist. Never start, stop, or adjust your dose without consulting your Karespot doctor.
